Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226586 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2018.10.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anatomic Location Predicts Response Rates: Real World Outcomes with Over 1,100 Cycles of Talimogene Laherparepvec (TVEC) Description: A Retrospective Review of a Prospectively Maintained Database.
Ann Surg
September 2025
Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Objective: We hypothesized that anatomic location of metastatic melanoma is associated with the degree of therapeutic response to TVEC.
Summary: TVEC is the first FDA-approved injectable oncolytic virus to treat unresectable stage IIIB-IV metastatic melanoma patients. Previously published real-world outcomes demonstrated a 39% complete response (CR) rate to TVEC.
Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric Subjects.
J Clin Pharmacol
September 2025
Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, CA, USA.
Oncolytic viruses are an emerging class of immunotherapies for cancer treatment. Talimogene laherparepvec (T-VEC) is a first-in-class oncolytic virus approved globally for advanced melanoma. Herein, we describe the quantitative clinical pharmacology aspects of T-VEC that supported the development of this unique therapy.
View Article and Find Full Text PDFOncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.
Vaccines (Basel)
August 2025
State Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, China.
Oncolytic virus (OV) immunotherapy, particularly with oncolytic herpes simplex virus (oHSV), has become a promising new strategy in cancer treatment. This field has achieved significant clinical milestones, highlighted by the FDA approval of Talimogene laherparepvec (T-VEC) for melanoma in 2015 and the approval of Teserpaturev/G47Δ for malignant glioma in Japan in 2021. This review synthesizes the key preclinical and clinical advancements in oHSV therapy over the last decade, critically analyzing the core challenges in target selection, genetic modification, administration routes, and targeted delivery.
View Article and Find Full Text PDFOncolytic viruses in head and neck cancers: clinical applications and therapeutic potential.
Front Microbiol
August 2025
Department of Radiation Oncology, All India Institute of Medical Sciences, Jodhpur, India.
Background: Head and neck squamous cell carcinoma remains a significant global health burden, particularly in low-resource regions like India. Conventional treatments often fall short in achieving durable responses, prompting the need for novel therapies.
Objective: This review outlines the clinical progress, mechanism of action, and emerging therapeutic potential of oncolytic viruses (OVs) in the management of HNSCC, with an emphasis on ongoing trials, approved agents, and future directions.
In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation.
Adv Sci (Weinh)
August 2025
South Australian ImmunoGENomics Cancer Institute, The University of Adelaide, Adelaide, SA, 5005, Australia.
Historically, directly injecting therapeutics into tumors has been deemed suboptimal and less favorable in clinical settings compared to systemic administration due to the inability to eradicate circulating/metastatic tumor cells until the emergence of the concept of in situ vaccine. In situ vaccine leverages patients' own tumors as a pool of antigens to elicit systemic antitumor immunity (also known as "abscopal effect") that aims to eliminate both primary and distal/metastatic tumors. One typical example of an approved product is Talimogene laherparepvec, an oncolytic virus approved in 2015 for treating advanced melanoma.
View Article and Find Full Text PDF